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homozygotes, GC heterozygotes and CC homozygotes (16, 0-256; 32, 0-256; 32, 0-64,
respectively; p=ns). Conclusion: Our data suggest that the C (-260) T polymorphism in
the promoter region of the CD14 receptor gene and the G (-174) C polymorphism of the
Interleukin 6 gene, are not involved in modulation of the individual immune response to
Cp infection in patients with ischaemic heart disease.
1136-89 ßeta-2 Receptors Are Upregulated in Canine Ventricles 
With a Chronic Myocardial Infarction
Philip B. Adamson, Travis Kanaly, Emilio Vanoli, Jennifer Suarez, Jeffrey Ardell, 
University of Oklahoma Health Sciences Center, Oklahoma City, OK, East Tennessee 
State University, Johnson City, TN
Background: Beta-1-adrenergic receptor densities decrease in end-stage cardiomyopa-
thy with no significant change in beta-2 or alpha receptor density. The relative densities of
beta-receptors after myocardial infarction (MI) with normal left ventricular function are
less well understood. This study examined beta-receptor densities in normal dogs and
compared them with animals 45 days after MI.
Methods: Four dogs were instrumented with an anterior MI by permanent ligation of the
left anterior descending (LAD) coronary artery during lateral thoracotomy. 45 days were
allowed for recovery and ventricular tissue was harvested during a terminal experiment.
Tissue in the LAD distribution was compared with tissue in the circumflex (Cx) territory in
post-MI dogs and normal animals (n=15). beta-receptor densities were measured with
receptor specific quantitative film autoradiography.
Results: beta-receptors from normal animals were not different between the LAD (7.6±3
fmol/mg, 76% beta-1; 2.3±0.6 fmol/mg, 23%, beta-2) and Cx (7.1±0.8 fmol/mg, 75%
beta-1; 2.3±0.2 fmol/mg, 25%, beta-2) tissues. Beta-2 receptor densities in post-MI dogs
were higher (p<0.04) in both the LAD (7.4±2 fmol/mg, 63%, beta-1; 4.3±1 fmol/mg, 37%,
beta-2) and the Cx (5.6±2 fmol/mg, 54%, beta-1; 4.7±2 fmol/mg, 46%, beta-2) territories,
while beta-1 receptor densities did not change.
Conclusions: Beta-2 adrenergic receptor densities increase following chronic MI and
comprise a larger percentage of available adrenergic receptors in canine ventricles.
These data may help explain why nonselective beta-blockers tend to be more effective in
post-MI clinical populations
1136-90 Relation of the –174 G/C and –572 G/C Promoter 
Polymorphisms of the Interleukin-6 Gene to Interleukin-
6 and Highly Sensitive C-Reactive Protein Serum Levels 
and to the Extent of Infarction in Acute Myocardial 
Infarction
Atiye Cengel, Aycan F. Erkan, Mehmet Ali Ergun, Derya Kan, Sevda Menevse, Gazi 
University School of Medicine, Ankara, Turkey
Background: GG homozygotes for -174 G/C polymorphism and carriers of C allele for
572 G/C have higher interleukin-6 (IL-6) levels and longer hospital stays after surgical
coronary revascularization. Our aim was to test the hypothesis that promoter polymor-
phisms of the IL-6 gene may be associated with the extent of acute myocardial infarc-
tion(AMI), and the degree of immunological response in AMI.
Methods: We enrolled 50 patients with the diagnosis of AMI. Patients with inflammatory
or infectious conditions, malignancy, recent trauma or surgery were excluded. Serum IL-6
and C-Reactive Protein (CRP) levels were determined on admission, and at 48 and 72
hours. Deoxy-ribo nucleic acid was extracted from peripheral blood and amplified with
polymerase chain reaction. The -174 G/C and -572 G/C genotypes were determined by
using primers. Left ventricular ejection fraction and wall motion score index (WMSI) were
calculated on trans-thoracic echocardiography.
Results: There are no significant differences between the GG, GC, and CC groups of
both polymorphisms according to infarct localization, therapy, and basal characteristics .
Baseline CRP and IL-6 levels were not significantly different, but the 48- and 72-hour
CRP and IL-6 levels were significantly higher in -174 GG patients when compared to-174
GC and CC patients.
Ejection fraction was significantly lower and WMSI was significantly higher in -174 GG
patients when compared to -174 GC and CC patients.
There were no statistically significant differences between -572 GG and GC (there were
no CC ) patients according to serum IL-6 and CRP levels, ejection fraction,and WMSI.
Conclusion:
We have demonstrated that GG homozygosity for the -174 G/C polymorphism is associ-
ated with higher serum IL-6 and CRP levels, and more extensive infarction evidenced by
lower ejection fraction and higher WMSI in AMI. There was no association of the 572 G/C
polymorphism with these conditions.
All these associations were independent from factors such as age, gender, diabetes,
hypertension, cigarette smoking, prior use of aspirin or statins , infarct localization, ther-
apy, and catheter-based mechanical revascularization.
1136-91 Contribution of Genetic Characteristics of Vascular 
Adrenergic Receptor to Variant Angina
Sang-Ho Jo, Jae-Bin Seo, Shu-Ying Zhang, Jin-Sik Park, Young-Seok Cho, Jin-Ho Choi, 
Bon-Kwon Koo, Yong-Jin Kim, Seil Oh, In-Ho Chae, Hyo-Soo Kim, Dae-Won Sohn, 
Byung-Hee Oh, Myoung-Mook Lee, Young-Bae Park, Yun-Shik Choi, Seoul National 
University College of Medicine, Seoul, South Korea, Seoul National University Hospital, 
Seoul, South Korea
Background: The α2 or β2-adrenergic receptor in vasculature mediate vasoconstriction or
dilation respectively in response to adrenergic agents, and β1-adrenergic receptor in
heart mediates chronotrophic and inotrophic changes. We hypothesized that adrenergic
receptor gene polymorphism is associated with vasospastic angina, and would explain
the different prevalence of variant angina between Koreans and Caucasians. We investi-
gate the relationship of vasospastic angina and four kinds of adrenergic receptor poly-
morphisms (α2c Del322-325, β2 Gly16, β2 Glu27 and β1 Arg389)
Methods: Vasospastic angina (N=162) was confirmed by focal coronary spasm in CAG
with chest pain or ST elevation on ECG after ergonovine intravenous infusion. Normal
control group comprised 129 subjects who showed normal coronary angiogram. After a
diagnostic coronary angiography was performed, four kinds of genotypes were identified
separately using different PCR and RFLP methods from the DNA extracted from the
peripheral monocytes.
Results: The allele frequencies of four kinds of adrenergic receptor polymorphisms (α2c
Del322-325, β2 Gly16, β2 Glu27 and β1 Arg389) in normal control were 0.23, 0.69, 0.53
and 0.17 respectively, and these are different from those of Caucasians (0.04, 0.61, 0.43,
0.73). The differences were prominent in α2c Del322-325 and β1 Arg389. The frequen-
cies of homozygosity for α2c Del322-325 polymorphism were significantly higher in vari-
ant angina group than in control, 16.4% and 0.8% respectively (p<0.0001). The
homozygosity for β2 polymorphism of codon 27(Glu27) is much less frequent in variant
angina group than in control(29.3% : 49.3%, p<0.0001). However, there was no differ-
ence in the prevalence of β2 polymorphism of codon 16(Gly16) or β1 polymorphism
between the two groups.
Conclusion: The Del (322-325) mutant of α2-receptor is a new genetic risk factors for
variant angina, and the Glu27 allele of the β2-adrenergic receptor is a negative risk factor
for variant angina. This is the first report in the world to demonstrate the contribution of
genetic characteristics of the vascular adrenergic system to coronary vasospasm.
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1137-77 Long-Term Cost-Effectiveness of Clopidogrel in 
Patients Having Percutaneous Coronary Intervention 
Early After Acute Coronary Syndrome: Results From 
PCI-CURE
William S. Weintraub, Elizabeth M. Mahoney, Shamir Mehta, Andre Lamy, Yong Yuan, 
Roland Chen, Joseph Jackson, Sylvie Gabriel, Olivier Bouin, Julie Spiesser, Salim Yusuf, 
Emory University, Atlanta, GA, McMaster University, Hamilton, ON, Canada
Background: The efficacy of clopidogrel up to 1 year after percutaneous coronary inter-
vention (PCI) following non-ST-elevation acute coronary syndrome (ACS) was demon-
strated in PCI-CURE.
Methods: We evaluated long-term cost effectiveness of clopidogrel after PCI during the
initial hospitalization in PCI-CURE; patients received clopidogrel pre-treatment (n=821)
or placebo (n=909). After PCI, >80% received open-label ADP-receptor antagonist for ~
4 weeks, then study drug for up to 1 year. This PCI-CURE subgroup characterizes US
PCI practice pattern. The composite CV death, stroke or MI occurred in 76 (9.3%) clopi-
dogrel vs 116 (12.8%) placebo patients (RR 0.73, p=0.02). Hospitalizations were
assigned a DRG; costs were estimated from: 1) Medicare, 2) MEDSTAT (private insur-
ance) , 3) MEDSTAT age <65 and Medicare age >65. Clopidogrel was assigned a cost of
$3.22/day. Lost life expectancy associated with CV death, MI and stroke was estimated
from Framingham data, discounted 3%. 95% CIs for costs differences were obtained by
bootstrap.
Results: 
The incremental cost-effectiveness ratio was $882/life year gained (LY) with Medicare
(37.6% dominant, 4.8% dominated, 90.8% <$50,000/LY), dominant with MEDSTAT
(58.1% dominant, 3.3% dominated, 91.7% <$50,000/LY), dominant with MEDSTAT/Medi-
care (56.0% dominant, 3.6% dominated, 92.0% <$50,000/LY).
Conclusions: Long-term clopidogrel therapy, up to 1 year after early PCI in the setting of
ACS, is both effective and highly cost-effective in cost per LY gained.
1137-93 Carvedilol Preserves Cellular Integrity and Improves 
Outcome in Patients With Chronic Hibernating 
Myocardium After Revascularization
Ernst R. Schwarz, Tuphoung Diep, Erik C. Skobel, Bernd Nowak, Sawa Kostin, Beate 
Grohmann, The University of Texas Medical Branch, Galveston, TX, Rheinisch 
Westfaelische-Technische Hochschule, Aachen, Germany
Chronic hibernating myocardium (HM) might undergo progressive cellular degeneration
and replacement fibrosis due to apoptosis and necrosis in the setting of recurrent myo-
cardial ischemia. Carvedilol has been shown to provide anti-oxidant and anti-apoptotic
effects in experimental animal studies in addition to its alpha- and beta-blocking effects.
Clopidogrel Placebo Difference 95% CI
Medicare Cost $14,856 $14,765 $91 -$713, $839
MEDSTAT Cost $20,195 $20,377 -$182 -$1,258, $837
MEDSTAT/Medicare $17,832 $17,987 -$155 -$1,131, $816
Lost Life Expectancy in 
Years (Framingham)
0.3426 0.4452 0.1027 -0.0452, 0.2581
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The effects of Carvedilol on myocardial morphology and functional outcome were studied
in patients with chronic HM undergoing cardio-vascular bypass grafting (CABG). Nine-
teen patients (13 males, 62+/-9 years) eligible for CABG due to severe CAD were ran-
domized into two groups: patients in group 1 (n=10) received Carvedilol (25 mg/day),
patients in group 2 received placebo (n=9), starting from randomization 7-8 weeks prior
to CABG until follow-up 4-6 months postoperatively, in addition to standard antianginous
therapy and aspirin. Left ventricular ejection fraction (EF) and regional wall motion abnor-
malities (WMA, centerline method) were quantitated in cineventriculography at baseline
and follow-up. Viability was assessed by Tc99m scintigraphy and F-18-FDG positron
emission tomography. Intraoperatively, transmural needle biopsies were obtained for
microscopic analysis and immunohistochemistry from hypokinetic but viable myocardial
regions. EF in group 1 increased from 31±5% to 44±4% postoperatively (p<0.005), EF in
group 2 increased from 30±6% to 40±6% (p<0.05 versus preoperatively and versus
group 1). WMA in the center of myocardial dysfunction in group 1 increased from -
2.1±0.4 to -0.6±0.5 (p<0.05), WMA in group 2 increased from -2.3±0.5 to -1.6±0.6
(p<0.05 versus pre and versus group 1). Microscopic analysis showed mild degenerative
changes in group1 with mild fibrosis (28±7%) and no evidence for apoptosis. Biopsies in
group 2 showed more apoptotic cell changes and progressive cardiomyocyte degenera-
tion but similar mild-to modest fibrosis (33±6%). Early treatment with Carvedilol in
patients with hibernating myocardium might delay progressive cardiomyocyte degenera-
tion possibly due to anti-apoptotic and anti-oxidant effects, which might result in improved
recovery of contractile function after revascularization.
1137-94 Age and the Lack of an Adverse Effect of Diabetes 
Explain the “Obesity Paradox” in Patients With 
Myocardial Infarction
Scott Wright, Joseph G. Murphy, Thomas G. Allison, Anil Nigam, Wayne L. Miller, Brent 
A. Williams, Ana G. Rosales, Guy S. Reeder, Allan S. Jaffe, Mayo Clinic, Rochester, MN
Background: The “obesity paradox” refers to improved survival among obese patients fol-
lowing acute myocardial infarction (AMI). The nature of this remains poorly defined.
Methods: We analyzed the outcome of 941 patients with AMI from 1988 until 2001. Obe-
sity was defined as BMI > 30, overweight as 25<BMI < 30 and normal weight as BMI <
25. Univariate and multivariate predictors of survival were analyzed.
Results: Obese patients were younger and less likely to be female at time of admission
(p<0.01). The prevalence of diabetes was higher in obese patients (24%) compared to
overweight (15%) or normal weight patients (13%), p <0.05. There were no differences in
other clinical characteristics. Long-term mortality was significantly lower in the obese (RR
0.64) and overweight (RR 0.76) patients compared to normal weight patients (RR 1.0),
p=0.04. Long-term survival among all three groups was less than age-predicted (see fig-
ure). Diabetes was not a univariate predictor of mortality risk in obese patients (RR NS)
but was in non-obese patients (RR 1.77, 95% CI 1.26, 2.48), p < 0.01. After adjustment
for age and diabetes, there were no longer significant differences: Obese (RR 0.74),
overweight (RR 0.83) vs normal (RR 1.0), p=0.14. Conclusion: The obesity paradox fol-
lowing AMI appears to be largely a function of younger age at time of presentation and
the lack of impact of concomitant diabetes. When adjusted for age, the long-term RR of
death in obese and overweight patients is similar to normal weight individuals 
1137-95 Demographics, Treatment, and Outcome of Acute 
Coronary Syndromes: 17 Years of Experience in a 
Tertiary Care Center
Jean-Pierre S. Awaida, Jocelyn Dupuis, Pierre Théroux, Michel Joyal, Pierre De Guise, 
Serge Doucet, Luc Bilodeau, Jean-François Tanguay, Richard Gallo, Jean Grégoire, 
Philippe Lavoie-Lallier, Laurent Macle, Anil Nigam, Montreal Heart Institute, Montreal, 
PQ, Canada
Background: There is limited epidemiological information about the evolution of demo-
graphics, treatment, and outcome of patients admitted to tertiary coronary care units
(CCU) over the past 15 years.
Methods: We prospectively studied 18,719 patients admitted from April 1986 to March
2003 in a 22 bed CCU. The attending physicians filled in the discharge form, which was
then entered in a computer database designed for the study.
Results: From 1986 till 2003, the number of admissions increased from 937 to 1577/year
while hospital stay decreased from 7.5 to 3.5 days; mean age increased from 58.4 to
63.4 years and the proportion of males remained stable at about 70%. Use of coronary
angiograms increased from 49.8% to 81.1% of all patients while fibrinolysis dropped from
12.2% to 0%. In-hospital mortality dropped from 9% to 1.5%. The percentage of Swan-
Ganz decreased from 8.1% to 0.7% while intra-aortic balloon pump insertion remained
stable. From 1995 till 2003, the proportion of stenting during PTCA increased dramati-
cally from 0 to 86%. In the past 5 years, surgical revascularization remained stable
around 20% of all admissions.
Conclusions: There has been a tremendous increase in efficiency with approximate
doubling of the admissions turnover rate in a tertiary care CCU. Patients with acute coro-
nary syndromes are stratified faster and treated more invasively. Therapeutic advances
are reflected by an almost linear 0.5%/year decrease of in-hospital mortality. 
1137-96 Clustering of Novel Risk Factors Correlates With the 
Metabolic Syndrome
Matthew A. Hook, John H. Chiu, Arman Askari, Niranjan Seshadri, Gregory L. Pearce, 
Dennis L. Sprecher, The Cleveland Clinic Foundation, Cleveland, OH
Background: Homocysteine, fibrinogen, lipoprotein (a) (Lp(a)), and C-reactive protein
(CRP) have been shown to be independently associated with cardiovascular dis-
ease.However, little is known regarding the clustering of these novel risk markers and
their correlation to the metabolic syndrome.
Methods: Data were collected from primary and secondary prevention patients entering
a cardiology clinic (n=1306, mean age 55 +/- 9 years, 36% female (n = 469), 19% diabet-
ics (n=243), mean waist circumference 98cm, 8% current tobacco users (n=110), mean
systolic blood pressure 122 mmHg, median LDL 126 mg/dL, median HDL 43 mg/dL),
including novel risk markers. We sought to determine whether the novel risk markers
were clustered in distribution and/or correlated to the variables of metabolic syndrome,
as defined by ATP III guidelines.
Results: These four novel biomarkers were clustered more than would be expected
under the assumption of independence (p<0.001). The expression of metabolic syn-
drome increased from 11% when none of the four were elevated to 28% when 3 or 4
were elevated (p<0.001). Conclusions: Homocysteine, fibrinogen, Lp(a) and CRP clus-
ter in an elevated state and are not independent of one another. The number of elevated
novel biomarkers directly correlates to the presence of the metabolic syndrome
1137-97 Soluble CD40 Ligand in Predicting Coronary Artery 
Disease and Long-Term Outcomes in Stable Patients 
With Angiographically Defined Disease States
Jason M. Lappe', John F. Carlquist, Jeffrey L. Anderson, Matthew J. Kolek, Benjamin D. 
Horne, Bryant M. Whiting, Heath U. Jones, Robert R. Pearson, Johnny Walker, Joseph B. 
Muhlestein, LDS Hospital, Salt Lake City, UT, University of Utah, Salt Lake City, UT
Background:
Elevated levels of soluble CD40 ligand (sCD40L) have been reported in patients with
acute coronary syndrome and have been found to independently predict risk of future
events in this population. However, to date, no study has correlated sCD40L levels and
the long-term risks associated with coronary artery disease (CAD) in non-MI patients.
Methods:
Serum sCD40L levels using ELISA (R&D; Systems) were measured in 909 patients eval-
uated by angiography for the presence of CAD. Patients presenting with acute MI were
excluded. A three-way matching scheme (by age [±5 years], gender, and time period of
catheterization [±1 year]) was used to identify 303 patients with CAD (>70% stenosis in
>1 major vessel) who experienced a cardiac event (death, MI) within one year, 303
patients with CAD but with no events at one year, and 303 with no CAD.
Results:
The three groups were balanced, with patient age averaging 64 + 11 years; 74% males.
Median (SE) sCD40L levels were different for no-CAD patients (335 [60] pg/mL) com-
pared to CAD (248 [65] pg/mL, p=0.01) and to CAD/event (233 [63] pg/mL, p<0.001) but
not between CAD and CAD/event patients (p=0.24). After separating sCD40L levels into
quartiles, performing logistic regression, adjusting for standard risk factors and C-reac-
tive protein, and performing Bonferroni adjustment for multiple comparisons (p-critical =
0.017), there was a non-significant trend toward decreased risk of CAD vs no-CAD (Q4
vs. Q1: odds ratio [OR]= 0.71, 95% confidence interval [CI]=0.44-1.13, p=0.15) and CAD/
event vs no-CAD (Q4 vs. Q1: OR=0.59, CI=0.37-0.96, p=0.03), but not for CAD/event vs.
CAD (Q4 vs. Q1: OR=0.89, CI=0.56-1.41, p=0.61). Analyses showed no differences
between men and women.
Conclusions:
In contrast to previously reported information in patients with acute coronary syndrome,
